Characterization of inhibitors of phosphodiesterase 1C on a human cellular system

FEBS Journal

Volumn 274, Issue 18, 2007, Pages 4812-4824

  Dunkern, Torsten R ^a   Hatzelmann, Armin ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

8 methoxymethyl 3 isoabutyl 1 methylxanthine; Glioblastoma cell line; Phosphodiesterase 1C; SCH51866; Vinpocetine

Indexed keywords

8 METHOXYMETHYL 3 ISOBUTYL 1 METHYLXANTHINE; CALCIUM; COMPOUND 30; COMPOUND 31; CYCLIC AMP; CYCLIC GMP; FORSKOLIN; IONOMYCIN; IONOPHORE; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PROTEIN; SCH 51866; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINPOCETINE;

ARTICLE; CALCIUM CELL LEVEL; CELL LINE; CELL MEMBRANE POTENTIAL; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CALCIUM; CALMODULIN; CELL LINE, TUMOR; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; ENZYME ACTIVATION; FORSKOLIN; GLIOBLASTOMA; HUMANS; IONOMYCIN; PHOSPHODIESTERASE INHIBITORS;

ANIMALIA;

EID: 34548428382     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.06001.x     Document Type: Article

References (30)

1. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Therapeutics 109, 366 398.
2. Polli JW Kincaid RL (1992) Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc Natl Acad Sci USA 89, 11079 11083.
3. Yu J, Wolda SL, Frazier AL, Florio VA, Martins TJ Snyder PB (1997) Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell Signal 9, 519 529.
4. Yan C, Zhao AZ, Bentley JK Beavo JA (1996) The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271, 25699 25706.
5. Rybalkin SD, Rybalkina I, Beavo JA Bornfeldt KE (2002) Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90, 151 157.
6. Torsney C, Anderson RL, Ryce-Paul KA Macdermott AB (2006) Characterization of sensory neuron subpopulations selectively expressing green fluorescent protein in phosphodiesterase 1C BAC transgenic mice. Mol Pain 2, 17 24.
7. Kostic MM, Erdogan S, Rena G, Borchert G, Hoch B, Bartel S, Scotland G, Huston E, Houslay MD Krause EG (1997) Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol 29, 3135 3146.
8. Han P, Werber J, Surana M, Fleischer N Michaeli T (1999) The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. J Biol Chem 274, 22337 22344.
9. O'Grady SM, Jiang X, Maniak PJ, Birmachu W, Scribner LR, Bulbulian B Gullikson GW (2002) Cyclic AMP-dependent Cl secretion is regulated by multiple phosphodiesterase subtypes in human colonic epithelial cells. J Membr Biol 185, 137 144.
10. Kanda N Watanabe S (2001) Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem Pharmacol 62, 495 507.
11. Fisch JD, Behr B Conti M (1998) Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors. Hum Reprod 13, 1248 1254.
12. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D Lauterbach R (2002) Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 300, 559 566.
13. Kovalev IV, Popov AG, Baskakov MB, Minochenko IL, Kilin AA, Borodin YL, Anfinogenova YD, Kapilevich LV Medvedev MA (2002) Effect of inhibitors of cyclic nucleotide phosphodiesterases on electrical and contractile activity of smooth muscle cells. Bull Exp Biol Med 133, 38 40.
14. Phillips PG, Long L, Wilkins MR Morrell NW (2005) cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 288, 103 115.
15. Bender AT, Ostenson CL, Wang EH Beavo JA (2005) Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation. Proc Natl Acad Sci USA 102, 497 502.
16. Kaneda T, Watanabe A, Shimizu K, Urakawa N Nakajyo S (2005) Effects of various selective phosphodiesterase inhibitors on carbachol-induced contraction and cyclic nucleotide contents in the guinea pig gall bladder. J Vet Med Sci 67, 659 665.
17. Murray F, Patel HH, Suda RY, Zhang S, Thistlewaite P, Yuan JX Insel PA (2006) Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension. Role for PDE1. Am J Physiol Lung Cell Mol Physiol 292, 294 303.
18. 2+]i increase in rat hippocampal CA1 pyramidal cells. Neurochem Res 26, 1095 1100.
19. Solntseva EI, Bukanova JV Skrebitsky VG (2001) The nootropic drug vinpocetine modulates different types of potassium currents in molluscan neurons. Comp Biochem Physiol C Toxicol Pharmacol 128, 275 280.
20. Zhou X, Dong XW, Crona J, Maguire M Priestley T (2003) Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther 306, 498 504.
21. Ukena D, Schudt C Sybrecht GW (1993) Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes. Biochem Pharmacol 45, 847 851.
22. Schudt C, Dent G Rabe KF (1996). Phosphodiesterase Inhibitors, pp. 21 40. Academic Press, London.
23. Ahn HS, Bercovici A, Boykow G, Bronnenkant A, Chackalamannil S, Chow J, Cleven R, Cook J, Czarniecki M, Domalski C et al. (1997) Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J Med Chem 40, 2196 2210.
24. Vemulapalli S, Watkins RW, Chintala M, Davis H, Ahn HS, Fawzi A, Tulshian D, Chiu P, Chatterjee M, Lin CC et al. (1996) Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol 28, 862 869.
25. Loughney K, Martins TJ, Harris EA, Sadhu K, Hicks JB, Sonnenburg WK, Beavo JA Ferguson K (1996) Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases. J Biol Chem 271, 796 806.
26. Corbin JD Johnson RA (1998) Initiation and termination of cyclic nucleotide action. Methods Enzymol 159, 491 500.
27. Raeburn D, Underwood SL, Lewis SA, Woodman VR, Battram CH, Tomkinson A, Sharma S, Jordan R, Souness JE Webber SE et al. (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113, 1423 1431.
28. Borbe HO, Hilboll G Prop G (1986) Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl 20, 249 257.
29. Thompson WJ Appleman MM (1979) Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cycl Nucleotide Res 10, 69 92.
30. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S Magnussen H (1993) Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 264, 458 464.